New progestins–Clinical experiences: Gestodene
- 1 May 1994
- journal article
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 170 (5) , 1562-1568
- https://doi.org/10.1016/s0002-9378(94)05020-9
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Oral contraceptive type and functional ovarian cystsAmerican Journal of Obstetrics and Gynecology, 1992
- Clinical experience with a modern low-dose oral contraceptive in almost 100,000 usersContraception, 1991
- Clinical acceptability of monophasic gestodeneAmerican Journal of Obstetrics and Gynecology, 1990
- Time-dependent alterations in lipid metabolism during treatment with low-dose oral contraceptivesAmerican Journal of Obstetrics and Gynecology, 1990
- Changes in lipid metabolism during 12 months of treatment with two oral contraceptives containing 30 μg ethinylestradiol and 75 μg gestodene or 150 μg desogestrelContraception, 1990
- A study comparing a gestoden triphasic formulation with a fixed combination OCAdvances in Contraception, 1989
- Gestoden, an innovative progestogenContraception, 1988
- Comparative Trial of the Effects on Glucose Tolerance and Lipoprotein Metabolism of two New Oral Contraceptives Containing Gestoden and DesogestrelActa Obstetricia et Gynecologica Scandinavica, 1988
- Ovarian neoplasms, functional ovarian cysts, and oral contraceptives.BMJ, 1987
- Effects of seven low dose combined oral contraceptives on high density lipoprotein subfractionsBJOG: An International Journal of Obstetrics and Gynaecology, 1987